2.8 C
Saturday, February 4, 2023

Checkmate (NASDAQ: CMPI) Announces its Acquisition by Regeneron

Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) disclosed that it has inked a definitive agreement for the purchase of Checkmate by Regeneron at an all-cash price of $10.50 per share of Checkmate common stock. The recommended purchase values Checkmate at a total equity value of around $250 million.

Regeneron stated that the company will continue to enhance and expand its immuno-oncology research efforts and that the purchase of Checkmate will add a promising new modality to Regeneron’s toolset of potential cancer treatments for difficult-to-treat malignancies. The integration of a distinct Toll-like receptor 9 with other antibody-based cancer treatments may improve therapeutic benefits and provide new treatment choices for patients in need.

The merger agreement calls for Regeneron to launch a tender offer for all outstanding shares of Checkmate common stock at an all-cash price of $10.50 per share of Checkmate common stock through a subsidiary. The tender offer will be prone to a series of requirements, including the tender of a majority of the outstanding shares of Checkmate common stock, the termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period, and other normal closing conditions.

Furthermore, Regeneron will buy all shares not purchased in the tender through a second-step merger if the tender offer is successful. The deal is expected to close in the middle of 2022. Wachtell, Lipton, Rosen & Katz is Regeneron’s legal counsel for the acquisition. Checkmate’s financial and legal advisors are Centerview Partners and Goodwin Procter LLP, respectively.

More articles


Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.